Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase
- 1 August 1990
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 33 (8) , 2073-2080
- https://doi.org/10.1021/jm00170a005
Abstract
The possibility of deriving a potent, cell-penetrating inhibitor of human erythrocyte PI 4-kinase, competitive with respect to ATP, has been investigated in a series of purine derivatives and analogues. The purine nucleus is not essential for binding to the ATP site but offers the advantage of synthetic accessibility to its derivatives. The optimum substitution pattern in purine was found to be an electron-releasing substituent in the 6-position (e.g. amino, as in adenine, 1) and a compact, lipophilic group in either the 8-position or, preferably, the 9-position, suggesting the importance of the N-1 lone pair and hydrophobic contributions of the 8- and 9-substituents to binding. The most potent inhibitor synthesized was 9-cyclohexyladenine (54), which has an apparent Ki value of 3.7 .mu.M.This publication has 4 references indexed in Scilit:
- Inhibition of phosphatidylinositol kinase in vascular smooth muscle membranes by adenosine and related compoundsBiochemical Pharmacology, 1987
- Adenosine and 5‘-chloro-5‘-deoxyadenosine inhibit the phosphorylation of phosphatidylinositol and myosin light chain in calf aorta smooth muscle.Journal of Biological Chemistry, 1985
- Analysis of the metabolic turnover of the individual phosphate groups of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Validation of novel analytical techniques by using 32P-labelled lipids from erythrocytesBiochemical Journal, 1984
- Synthesis and bronchodilating activity of 2,9-disubstituted adenine derivatives: BB-1502 (9-cyclohexy-2-n-propoxy-9H-adenine) and its analogs.CHEMICAL & PHARMACEUTICAL BULLETIN, 1982